also developed a BP‐based DDS synergistic therapy using PTT/PDT/chemotherapy to effectively inhibit chemotherapy‐resistant tumor cells.[67] The p53 gene is believed to be closely related to cell drug resistance, as mutations in the p53 gene are often associated with drug‐resistant tumors, so reducing the mutation level of the p53 gene is an effective way to solve drug resistance.[241, 242, 243, 244] In one study, DOX was loaded on a BP DDS, along with phenethyl isothiocyanate (PEITC), which can decrease mutant p53 levels and enhance chemotherapy drug sensitivity. Here, TP53 is linked to neoplasm.